Semaglutide and retatrutide shrink liver fat

Fatty liver disease sounds vague. It isn’t. In people with obesity or type 2 diabetes, fat builds up inside the liver, then inflammation and scarring can follow, and that can end in cirrhosis, cancer, or transplant. The big shift now is that obesity drugs are no longer just helping the scale — they’re showing direct-looking liver effects strong enough to change how MASH gets treated. Semaglutide has already posted phase 3 biopsy data and moved into guidelines and approvals, while retatrutide is making people pay attention because the liver-fat numbers are enormous. ### What disease are we talking about? MASLD is the broad category — metabolic dysfunction–associated steatotic liver disease. MASH is the more dangerous form, where fat in the liver is joined by inflammation and cell injury, often with fibrosis, which is scarring. This is common in diabetes, not rare edge-case hepatology. The ADA’s 2025 consensus report said liver steatosis affects about two out of three people with type 2 diabetes, and that liver disease has been under-screened compared with eye, kidney, and nerve complications. (gi.org) ### What did semaglutide actually show? The cleanest evidence comes from the phase 3 ESSENCE trial. In the 72-week interim analysis, semaglutide 2.4 mg once weekly led to MASH resolution without worsening fibrosis in 62.9% of patients, versus 34.3% on placebo. It also improved fibrosis by at least one stage without worsening steatohepatitis in 36.8% versus 22.4%. That matters because earlier GLP-1 stories in liver disease often looked stronger on inflammation than on scarring. (diabetesjournals.org) Here, both primary endpoints landed. ### Why is that a big deal? Because biopsy endpoints are the hard currency in MASH. Lots of drugs can improve liver enzymes or imaging. Fewer can show that liver tissue itself looks better under the microscope. Semaglutide did that in a large global trial with 800 patients across 37 countries, which is why the result carried enough weight to support regulatory action and clinical adoption. The EU has conditionally authorized semaglutide for MASH, and in the U.S. the FDA approved Wegovy for adults with non-cirrhotic MASH and moderate to advanced fibrosis in 2025. (gi.org) ### So where does retatrutide fit? Retatrutide is Lilly’s triple agonist — GIP, GLP-1, and glucagon. It is earlier-stage in liver disease, but the liver-fat data are the kind that make the whole field stop and stare. In an MASLD substudy from a 48-week phase 2 obesity trial, liver fat fell by 81.4% and 82.4% at 24 weeks with the 8 mg and 12 mg doses, and by 81.7% and 86.0% at 48 weeks. By week 48, liver fat dropped below 5% — basically the threshold used to define steatosis resolution — in 89% and 93% of patients on those top doses. (gi.org) ### Is that just weight loss in disguise? Not entirely, but weight loss is clearly a huge part of it. In the retatrutide substudy, liver-fat reduction tracked strongly with body-weight change, with near-maximal liver-fat reduction showing up around 20% weight loss. That suggests the liver benefit is tightly linked to the drug’s extreme weight-loss effect. But the metabolic pattern also looks broader — insulin resistance improved, triglycerides fell, adiponectin rose, and markers tied to lipid handling shifted fast. (aasld.org) Basically, the liver is not acting like a passive passenger here. ### Why are people excited now? Because the field has crossed from “interesting signal” to “treatment stack.” Resmetirom opened the door in 2024. Semaglutide showed a widely used incretin can hit biopsy endpoints too. ADA documents now explicitly treat MASLD and MASH as a diabetes-management problem that needs screening and early intervention, not a side quest. That creates room for combinations, earlier treatment, and a lot more competition among GLP-1, dual-agonist, and triple-agonist programs. (aasld.org) ### What’s the catch? Retatrutide’s headline numbers are on liver fat by MRI-PDFF, not yet phase 3 biopsy outcomes in MASH. Semaglutide has the stronger proof on histology today. So the current picture is simple — semaglutide is the validated liver drug with obesity-drug roots, and retatrutide is the next-wave contender with eye-popping fat-reduction data but more to prove on fibrosis and long-term outcomes. (diabetesjournals.org) ### Bottom line? These drugs are changing the mental model. For years, fatty liver therapy meant modest effects, specialist care, and not much momentum. Now one incretin drug has cleared the biopsy bar, and another has shown that liver fat can collapse at a scale that used to look unrealistic. That doesn’t mean MASH is solved. But it does mean the center of gravity has moved — fast. (gi.org)